Hepatitis C Treatment Market Size, Share & Forecast to 2030

The global market for Hepatitis C Treatment is estimated at US$109.1 Billion in 2023 and is projected to reach US$224.6 Billion by 2030, growing at a CAGR of 10.9% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the hepatitis C treatment market is driven by several factors. Technological advancements in drug formulation and delivery have enhanced treatment efficacy and patient compliance. The increasing prevalence of hepatitis C, particularly among high-risk populations, has escalated the demand for effective treatments. Enhanced diagnostic techniques and widespread screening programs enable early detection and prompt intervention, broadening the treatment landscape. Regulatory approvals of new and improved DAAs, coupled with robust investment in research and development by pharmaceutical companies, fuel market expansion.

Public health initiatives and international efforts to eliminate hepatitis C also significantly contribute to market growth. Additionally, partnerships between stakeholders, including governments, healthcare providers, and pharmaceutical companies, foster innovation and accelerate the availability of advanced treatment options. These factors collectively drive the dynamic and rapidly evolving hepatitis C treatment market.

Key Insights:

Market Growth: Understand the significant growth trajectory of the HCV Protease Inhibitors Drug Class segment, which is expected to reach US$25.3 Billion by 2030 with a CAGR of a 9.3%. The HCV Polymerase Inhibitors Drug Class segment is also set to grow at 10.5% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $29.5 Billion in 2023, and China, forecasted to grow at an impressive 14.8% CAGR to reach $49.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Hepatitis C Treatment Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hepatitis C Treatment Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Hepatitis C Treatment Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as AbbVie, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 123 Featured):

AbbVie, Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Kadmon Holdings, Inc.
Merck & Co., Inc.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Global Economic Update
Hepatitis C Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Introduction of Direct-Acting Antivirals (DAAs)
High Cure Rates with Shorter Treatment Durations
Increasing Screening and Diagnosis Rates
Rising Awareness and Government Initiatives
Development of Pangenotypic Regimens
Growing Focus on HCV Elimination Programs
Advancements in Liver Disease Management
Increasing Investment in R&D Activities
Expanding Access to Healthcare in Developing Regions

4. GLOBAL MARKET PERSPECTIVE

TABLE 1: World Hepatitis C Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Hepatitis C Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for HCV Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for HCV Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for HCV Protease Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for HCV Polymerase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for HCV Polymerase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for HCV Polymerase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for HCV NS5A Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for HCV NS5A Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for HCV NS5A Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Interferon & Antiviral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Interferon & Antiviral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Interferon & Antiviral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

CANADA

TABLE 23: Canada Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

JAPAN

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Japan 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

CHINA

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: China Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: China 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

EUROPE

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Hepatitis C Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Europe 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

FRANCE

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: France Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: France 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

GERMANY

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Germany 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

ITALY

TABLE 44: Italy Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Italy 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

UNITED KINGDOM

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: UK Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: UK 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

SPAIN

TABLE 50: Spain Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Spain 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

RUSSIA

TABLE 53: Russia Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Russia 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

REST OF EUROPE

TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Rest of Europe 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Hepatitis C Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Hepatitis C Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Hepatitis C Treatment by Drug Class - HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Asia-Pacific 16-Year Perspective for Hepatitis C Treatment by Drug Class - Percentage Breakdown of Value Sales for HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral for the Years 2014, 2024 & 2030

AUSTRALIA

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)

INDIA

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)

SOUTH KOREAREST OF ASIA-PACIFIC

LATIN AMERICA

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)

ARGENTINABRAZILMEXICOREST OF LATIN AMERICA

MIDDLE EAST

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)

IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST

AFRICA

Hepatitis C Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)

IV. COMPETITION

Companies Mentioned

AbbVie, Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Kadmon Holdings, Inc.
Merck & Co., Inc.

Table Information

Report Attribute	Details
No. of Pages	208
Published	November 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 109.1 Billion
Forecasted Market Value ( USD ) by 2030	$ 224.6 Billion
Compound Annual Growth Rate	10.9%
Regions Covered	Global
No. of Companies Mentioned	8

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5325EUR$5,450USD£4,445GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10117EUR$10,355USD£8,446GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15975EUR$16,350USD£13,336GBP

Hepatitis C Treatment - Global Strategic Business Report

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 123 Featured):

Table of Contents

Companies Mentioned

Table Information

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 123 Featured):

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Hepatitis C Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Hepatitis C Drug Market

Alcoholic Hepatitis Treatment - Global Strategic Business Report

Hepatitis Test Solution/Diagnosis - Global Strategic Business Report

Hepatitis C Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

About the Hepatitis C Drug Market